Turku-based bioprinting startup Brinter said it has closed €1.2M seed funding round led by early-stage VC Innovestor as it seeks to expand its operations internationally in Europe and the United States.
The 2019-founded Brinter aims to put bioprinting within reach of every pharmaceutical company, hospital, university, and research center. It said it saw fast market growth as accelerated technological, material, and methodological developments expand the potential applications for 3D-bioprinting. Brinter can speed up this scientific development by a factor of up to ten.
“Companies like Brinter are paving the way for 3D bioprinting, revolutionizing the future of medicine to the point where a customized heart or kidney can be made for a transplant patient..”Wilhelm Lindholm, CEO of Innovestor
Customers of the company include bio and pharmaceutical companies like Nanoform, as well as research organizations like VTT, BEST group at the University of Glasgow, Johannes Gutenberg University of Mainz, the University of Oulu, and the University of Helsinki.
“I am extremely excited to continue our 3D brain printing project with Brinter. The brain is an extremely vulnerable organ and target of various incurable diseases with the highest societal impact. Combined with two other rapidly-developing technologies – stem cells and biomaterials – 3D-bioprinting will soon provide us with fine-tuned human mini-brains and brain prosthetics, thereby deepening our understanding of the human mind and our ability to combat serious brain disorders,” said Jari Koistinaho, MD, Ph.D., Professor of Regenerative Medicine, University of Eastern Finland and Director of Neuroscience Center & Professor of Neuropharmacology at the University of Helsinki.